Yazar "Kizmaz, Muhammet" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    Evaluation of Netrin-1 Levels and Albuminuria in Patients With Diabetes
    (JOHN WILEY & SONS INC, 2016) Ay, Emre; Marakoglu, Kamile; Kizmaz, Muhammet; Unlu, Ali
    BackgroundNetrin-1 is a diagnostic biomarker that has been identified recently for chronic renal failure (CRF) in animal experiments. Netrin-1 levels in urine have been shown to have increased significantly at the acute kidney damage. Human studies on the relation between the CRF and plasma netrin-1 levels have not been found in the literature. This study aimed to investigate whether plasma netrin-1 levels increased in the early stages of the CRF in diabetic patients. MethodsPlasma samples from healthy volunteers and diabetic patients with and without microalbuminuria were collected after receiving consent. Netrin-1 in plasma was quantified by enzyme-linked immunosorbent assay and the data were analyzed to determine whether plasma netrin-1 correlates significantly with disease progression. ResultPlasma netrin-1 level in microalbuminuric diabetic patients was significantly higher than in normoalbuminuric diabetic patients and the control group. However, no significant difference between normoalbuminuric patients and control group was determined. Plasma netrin-1 level was significantly associated with albuminuria and estimated glomerular filtration rate, independently of age and sex. ConclusionThis study supports that plasma netrin-1 level increases significantly when glomerular damage occurs in diabetic nephropathy.
  • Küçük Resim Yok
    Öğe
    Evaluation of pharmacologic therapies accompanied by behavioural therapy on smoking cessation success: a prospective cohort study in Turkey
    (TAYLOR & FRANCIS LTD, 2017) Marakoglu, Kamile; Kargin, Nisa Cetin; Ucar, Rahime Merve; Kizmaz, Muhammet
    OBJECTIVE: The main objective of this study is to compare the rate of smoking cessation in the first month, third month, sixth month, first-year, and second year among those who quit smoking following different pharmacological and behavioural therapies administered at the Selcuk University's Smoking Cessation Clinic in Turkey. METHODS: In this study, 3322 people who presented to the clinic in order to quit smoking were advised one of the most suitable medical treatments (varenicline, bupropion, NRT) accompanied by behaviour therapy after their health queries and examinations were made and Fagerstrom scores were evaluated. Smoking cessation patients were followed up clinically and by making calls after smoking cessation. RESULTS: The smoking cessation success rate in the cases using varenicline in the first month was 63.5% (766/1206), in the third month 46.8% (548/1170), in the sixth month 32.1% (386/1201), first year 25.6% (298/1163), and 19.9% (211/1059) in the second year. The success rate in the cases using bupropion in the first month was 49.9% (559/1120), in the third month 35.6% (405/1138), in the sixth month 26.4% (319/1210), first year 21.9% (261/1192), and 16.0% (133/832) in the second year. The success rate in the cases using NRT was 53.2% (25/47) in the first-month, 24.3% (9/37) in the third-month, and 27.3% (6/22) in the sixth-month assessments. The rates of smoking cessation in the cases using varenicline and behavioural therapy in the 1st, 3rd, 6th, 12th, and 24th month were significantly higher compared to the cases using bupropion and behavioural therapy (p =.000, p =.000, p =.008, p =.034, and p =.028; respectively). CONCLUSIONS: It has been observed in this study that varenicline as a smoking cessation drug is better tolerated than other medications and it seems to be more effective.
  • Küçük Resim Yok
    Öğe
    Plasma netrin-1 levels significantly increase in smokers
    (PERGAMON-ELSEVIER SCIENCE LTD, 2016) Kizmaz, Muhammet; Marakoglu, Kamile; Kiyici, Aysel; Ay, Emre
    Objectives: Netrin-1 is a laminin like protein that has recently been suggested to involve in the pathophysiology of atherosclerosis and treatment targets. The relationship between netrin-1 and atherosclerosis has not been evaluated in a human research previously and the effect of smoking on plasma netrin-1 levels as well. In this study, we aimed to evaluate plasma netrin-1 levels in smokers and non-smokers and the impact of smoking on netrin-1 levels. Our second aim was to evaluate the existence of peripheral artery disease in these groups by means of ankle brachial index (ABI) measurements and the relation between plasma netrin-1 levels and peripheral artery disease. Design and Methods: Smoker and non-smoker male patients were contributed in the study, 112 males in each group. ABI of all patients was determined with an automatic device and plasma netrin-1 levels were quantified with an enzyme-linked immunosorbent assay. Netrin-1 levels were compared between smoker and non-smoker cases, and the cases with and without peripheral arterial disease. Results: Plasma netrin-1 levels of smokers (4.54 +/- 2.87 pg/mL) were significantly higher than in non-smokers (3.81 +/- 1.26 pg/mL) (p = 0.015). Similarly, netrin-1 levels of cases with peripheral arterial disease (6.21 +/- 2.16 pg/mL) were significantly higher than the ones without peripheral arterial disease (4.07 +/- 2.16 pg/mL) (p = 0.002). Amount of smoking (packet.year) and ABI were found to be significantly related with netrin-1 levels. The relationship between PAD and netrin-1 levels remained significant after adjusting for smoking status. Conclusion: We can conclude that plasma netrin-1 levels significantly increase in smokers and peripheral artery disease is significantly related with netrin-1 levels after adjusting for smoking status. (C) 2016 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.